The effects of medications used for the management of dyslipidemia on postprandial lipemia

Current Medicinal Chemistry
Nicholas TentolourisN Katsilambros

Abstract

Postprandial lipemia has emerged as an independent risk factor for coronary artery disease. In this systematic review we examined the effect of the medications used for the management of dyslipidemia on postprandial lipemia. Statins, beyond their effects on fasting lipid levels, reduce also postprandial lipemia mainly by inhibiting the production of apoB containing lipoproteins from the liver and thus increasing the clearance of triglyceride-rich lipoproteins of either liver or intestinal origin. Fibrates decrease fasting triglyceride and increase high density lipoprotein cholesterol levels. Besides, fibrates are particularly potent drugs in the reduction of postprandial lipemia; they decrease the production or triglyceride-rich lipoproteins and increase their clearance by enhancing the activity of lipoprotein lipase.

Associated Clinical Trials

Citations

Aug 12, 2009·Current Atherosclerosis Reports·Domenic A Sica
Jul 12, 2014·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Christian WernerUlrich Laufs
Feb 11, 2012·Canadian Journal of Physiology and Pharmacology·Tatyana A KorolenkoVassilij I Kaledin
Nov 8, 2011·British Journal of Clinical Pharmacology·Jean Davignon

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.